Tendyne Holdings has secured USD25m in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors.
Proceeds will be used for validation of Tendyne's novel Transcatheter Mitral Valve Implant to treat mitral regurgitation, including forthcoming clinical trials.
"This financing is a significant milestone for Tendyne. In 2013 Tendyne demonstrated positive human data and this infusion of capital allows us to move ahead confidently as we accelerate our minimally invasive mitral valve programme," says Jeff Franco, founder and CEO of Tendyne. "We are excited to have Apple Tree Partners come on board. We look forward to benefiting from their experience as we develop our technology and clinical presence."
Formed in 2010, Tendyne's first product is a transcatheter mitral valve replacement prosthesis for the treatment of both functional and degenerative mitral regurgitation. Tendyne's mitral valve is deployed and secured while preserving the sub-valvular apparatus. The Tendyne valve will initially be implanted transapically in a simple procedure that allows the physician to re-position or retrieve the valve after full deployment.
David McIntyre, a partner at Apple Tree Partners, will join the board of directors at Tendyne.
